Defense Language Institute Foreign Language Center

New collaboration and funding to expand clinical evidence for Syantra's patent-pending Onco-ID™ cancer detection platform CALGARY, AB, Feb. 26, 2025 /PRNewswire/ - Syantra, Inc., a precision biotechnology company revolutionizing cancer detection, today announced that it has received funding from Alberta Innovates to support expanded clinical studies for investigating the Onco-ID™: Breast blood test in women at elevated risk of breast cancer. The funding from Alberta Innovates AICE (Accelerating Innovations into CarE) Market Access program will both complement recent funding by the United States Department of Defense and support a pilot study with Jessica Treviño Jones, MD, of the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). "We are honored to receive both the funding and the recognition that comes with the AICE award," said Syantra CEO, Rob Lozuk. "We look forward to leveraging our science with the support of this transformative grant to improve early cancer detection." The AICE funding will support critical work for FDA filings and Syantra's move into the US market. This includes expanding clinical validation data for women with dense breast tissue and other risk factors and generating pilot data on the use of the test. "Syantra is another example of Alberta's innovators striving to solve real world challenges. Working with international partners to enable the early detection of breast cancer through the use of their blood test and facility here in Calgary is a compelling demonstration of the way we generate impact," said Tim Murphy, Vice President, Health, Alberta Innovates. Syantra will be working in collaboration with Dr. Jones, an associate professor and breast medical oncologist in the Division of Hematology and Oncology at UT Health San Antonio. She is also the founder and director of Mays Cancer Center's Cancer Risk Reduction and Education Clinic. "I am excited to be working on this project with Dr. Jones who is on the front-lines of breast cancer screening, and working towards early detection and treatment. This two-year project will recruit 500 new participants into the clinical validation study for the Onco-ID blood test for breast screening to complement existing global recruitment. The project will also support a pilot study on use of the test in women at elevated risk of developing breast cancer. This will enable collection of data to help inform positioning for commercial use," said Kristina Rinker, PhD, PEng, Syantra co-founder and project lead. "With recognition by AICE, the grant from the DoD, and formation of our new Scientific Advisory Board, Syantra is getting closer to market entry for Onco-ID, our patent-pending platform that leans into the body's own immune system, identifying the presence of early-stage cancer," said Lozuk. "We look forward to 2025 being a monumental year for Syantra." About Syantra Founded by a Calgary-based team of innovators in biomedical engineering and medicine and supported by world-leading clinicians, Syantra Inc. is a privately held, precision biotechnology company pioneering a platform to change the way cancer is detected and managed. For more information, visit , or contact [email protected]. SOURCE Syantra Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MINNEAPOLIS--( BUSINESS WIRE )--Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. BIO 300 is an oral drug that patients self-administer daily for 12 weeks following hospital discharge. The study compared the lung function, exercise capacity, and quality of life in COVID-19 survivors who received BIO 300 against a placebo group. The trial enrolled 38 participants across multiple U.S. sites ( NCT04482595 ). Rany Condos, MD, a clinical Professor in the Department of Medicine at NYU Grossman School of Medicine and Director of its Post-COVID Program, served as the lead investigator. Patients previously hospitalized with COVID-19 complications and discharged with residual lung complications (e.g., long COVID) were eligible if enrolled within two years of discharge. Multiple pulmonary function assessments and a patient-reported quality of life questionnaire were used to evaluate BIO 300’s efficacy. Although the study fell short of its planned enrollment of 50 participants, the 20 BIO 300-treated participants within the enrolled cohort of 38 exhibited improved lung function and participant-reported quality of life compared to placebo-treated participants. Key Trial Findings: Improvement in Pulmonary Function: Participants who received BIO 300 demonstrated a statistically significant improvement in pulmonary function at 12 weeks, which was maintained at 12 months, as measured by forced expiratory volume in one second (FEV1). Additionally, clear statistical trends for improved pulmonary function were observed in BIO 300-treated participants at 12 weeks, 6 months, and 12 months, as measured by the diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC). Quality of life: Participants treated with BIO 300 showed a clear trend toward an improved quality of life as measured by the St. George’s Respiratory Questionnaire at 6 months, which was maintained at 12 months. Safety Profile: BIO 300 treatment was well-tolerated, with adverse events consistent with those expected in this patient population. No new safety concerns were identified during the trial. "We are highly encouraged by the results of this clinical trial, particularly the promising trends in pulmonary function improvement among COVID-19 participants treated with BIO 300," said Michael Kaytor, PhD, Vice President of Research and Development at Humanetics. "We are continuing to evaluate the data to refine our understanding of BIO 300’s efficacy in COVID-19 and its potential applications for improving patient outcomes." BIO 300 is also in development as a medical countermeasure for use by the United States Department of Defense and for oncology applications to protect patients from side effects caused by radiation. "As BIO 300 has been shown to mitigate inflammation of the lungs and pulmonary fibrosis caused by radiation, we believe that the same effect can be shown in COVID-19 patients,” said Ronald J. Zenk, Chief Executive Officer at Humanetics. “We are optimistic that this treatment could be a valuable addition to the ongoing efforts to combat long COVID and other conditions with lung inflammation and are committed to evaluating its impact in future studies.” This project was funded by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, Department of Health and Human Services, under Contract HHSN272201800011C. About Humanetics Corporation Humanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases. For more information, visit www.humaneticscorp.com .

MINNEAPOLIS--( BUSINESS WIRE )--Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. BIO 300 is an oral drug that patients self-administer daily for 12 weeks following hospital discharge. The study compared the lung function, exercise capacity, and quality of life in COVID-19 survivors who received BIO 300 against a placebo group. The trial enrolled 38 participants across multiple U.S. sites ( NCT04482595 ). Rany Condos, MD, a clinical Professor in the Department of Medicine at NYU Grossman School of Medicine and Director of its Post-COVID Program, served as the lead investigator. Patients previously hospitalized with COVID-19 complications and discharged with residual lung complications (e.g., long COVID) were eligible if enrolled within two years of discharge. Multiple pulmonary function assessments and a patient-reported quality of life questionnaire were used to evaluate BIO 300’s efficacy. Although the study fell short of its planned enrollment of 50 participants, the 20 BIO 300-treated participants within the enrolled cohort of 38 exhibited improved lung function and participant-reported quality of life compared to placebo-treated participants. Key Trial Findings: Improvement in Pulmonary Function: Participants who received BIO 300 demonstrated a statistically significant improvement in pulmonary function at 12 weeks, which was maintained at 12 months, as measured by forced expiratory volume in one second (FEV1). Additionally, clear statistical trends for improved pulmonary function were observed in BIO 300-treated participants at 12 weeks, 6 months, and 12 months, as measured by the diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC). Quality of life: Participants treated with BIO 300 showed a clear trend toward an improved quality of life as measured by the St. George’s Respiratory Questionnaire at 6 months, which was maintained at 12 months. Safety Profile: BIO 300 treatment was well-tolerated, with adverse events consistent with those expected in this patient population. No new safety concerns were identified during the trial. "We are highly encouraged by the results of this clinical trial, particularly the promising trends in pulmonary function improvement among COVID-19 participants treated with BIO 300," said Michael Kaytor, PhD, Vice President of Research and Development at Humanetics. "We are continuing to evaluate the data to refine our understanding of BIO 300’s efficacy in COVID-19 and its potential applications for improving patient outcomes." BIO 300 is also in development as a medical countermeasure for use by the United States Department of Defense and for oncology applications to protect patients from side effects caused by radiation. "As BIO 300 has been shown to mitigate inflammation of the lungs and pulmonary fibrosis caused by radiation, we believe that the same effect can be shown in COVID-19 patients,” said Ronald J. Zenk, Chief Executive Officer at Humanetics. “We are optimistic that this treatment could be a valuable addition to the ongoing efforts to combat long COVID and other conditions with lung inflammation and are committed to evaluating its impact in future studies.” This project was funded by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, Department of Health and Human Services, under Contract HHSN272201800011C. About Humanetics Corporation Humanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases. For more information, visit www.humaneticscorp.com .